Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix and Iconix to Co-develop Drug Toxicology Research Tools

NEW YORK, Feb. 7 (GenomeWeb News) - Affymetrix and Iconix Pharmaceuticals plan to co-develop products to help study the toxicological and pharmacological properties of drugs and drug candidates, the firms said today.

 

Under the terms of the agreement, Affymetrix will combine its GeneChip platform with Iconix's DrugMatrix 640 compound reference database and analysis software. Researchers will also be able to compare gene-expression profiles to Iconix's Drug Signatures library to help predict the impact that gene-expression changes may have on the body's toxic response, the companies said.

 

Financial terms were not disclosed.